OVID NASDAQ
Ovid Therapeutics Inc.
1W: -4.2%
1M: -8.1%
3M: -1.3%
YTD: +28.4%
1Y: +38.6%
3Y: -34.9%
5Y: -37.6%
$2.26
+0.10 (+4.87%)
Weekly Expected Move ±9.9%
$2
$2
$2
$2
$3
Credit Risk of going bust: lower than 54% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.6%), Ovid Therapeutics Inc. would be worth roughly what it owes.
Total debt $12.7M against a stock market value of $441.4M.
Distance to default 5.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $6.4M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 7.19. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.6%), Ovid Therapeutics Inc. would be worth roughly what it owes.
Total debt $12.7M against a stock market value of $441.4M.
Distance to default 5.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $6.4M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 7.19. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-01-03
Earliest Filing
2023-10-18
Latest Filing
partner: 2
acquirer: 1
Counterparties (Filed by OVID)
3 relationshipsCompanies named in OVID's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | LGNZZ | acquirer | Acquired a 13% interest in soticlestat royalties and milestones from Ovid Therapeutics for $30 million. | 2023-10-18 | View |
| Takeda Pharmaceutical Company Limited | TKPHF | partner | Holds the primary Royalty, License and Termination Agreement for soticlestat with Ovid and is responsible for advancing | 2023-10-18 | View |
| AstraZeneca AB | AZN | partner | Entered into a License Agreement granting Ovid Therapeutics exclusive rights to develop and commercialize AstraZeneca's | 2022-01-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-13 | Exhibits | View | |
| 2026-07-08 | Officer/Director Change | View | |
| 2026-06-11 | Shareholder Vote | View | |
| 2026-06-03 | Officer/Director Change | View | |
| 2026-05-12 | Exhibits | View | |
| 2026-04-20 | Other Events | View | |
| 2026-03-18 | Material Agreement; Earnings Release; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2025-12-18 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-11 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-10-03 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Amendments to Art | Agreement | View |
| 2025-09-16 | Other Events | View | |
| 2025-08-13 | Financial Statements and Exhibits | View | |
| 2025-07-10 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-25 | Other Events | View | |
| 2025-05-13 | Results of Operations and Financial Condition | View | |
| 2025-05-02 | Shareholder Nominations | View | |
| 2025-03-11 | Results of Operations and Financial Condition | View | |
| 2025-03-05 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-02-13 | Notice of Delisting or Transfer | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR